Some Promising Areas Of Research Into CBD

The relationship between infection and standard antibiotics

Could CBD flavor work in the fight against resistant bacterial pressures? The arise from the University of Queensland in Australia recommend that it is possible. But prior to taking a look at the research study in depth, it is useful to comprehend the evolution of the relationship between germs and antibiotics.

Considering that the advanced discovery of penicillin by Alexander Fleming in 1928, antibiotics have been an essential tool in the fight against germs and infections. And although we still utilize the very same tested approaches today, germs have evolved. When exposed to antibiotics, particular germs, fungis and parasites have the ability to adjust and cancel the effectiveness of the drug by establishing resistance.

It’s worth pointing out that antimicrobial resistance was likely to occur anyway, as the hereditary code for germs changes over time. However, it is believed that the overuse of antibiotics is a crucial factor that accelerates the development of resistant pressures.

According to the World Health Organization, antimicrobial resistance “is an increasingly serious danger to worldwide public health that requires action in all sectors of federal government and in society.” This has actually led scientists to believe outside the box by trying to recognize compounds that could be useful in the fight against hazardous germs. One of these compounds is cannabidiol (CBD), a cannabinoid found in Cannabis sativa.

Researchers are trying to find new ways to attack infections and resistant germs.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that nine CBD is effective against Gram-positive germs. Stress of Gram-positive germs consist of Staphylococcus aureus (common in skin infections) and Streptococcus pneumoniae (common in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual meeting of the American Society for Microbiology. In vitro samples of both kinds of gram-positive germs were treated with synthetic CBD. The results led Dr. Blaskovich to the conclusion that CBD works at levels similar to those of prescription antibiotics vancomycin and daptomycin. He also discovered that CBD appeared to work against gram-positive pressures of resistant germs, which many standard antibiotics are starting to fail.

” In specific, the activity was picked against the resistant pressures of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to induce resistance and was active against MRSA biofilms. “

The team also conducted another research study using topical CBD to deal with a skin infection in mice. Again, although the results were positive, CBD did not appear to eliminate the infection, however just to lower the number of bacterial cells.

Could CBD become an antibiotic?

While it is simple to hail this work as a significant breakthrough in the anti-bacterial abilities of CBD, it is prematurely to give up on penicillin.

Although it is believed that the effectiveness of CBD might come from the method it assaults the biofilm surrounding bacterial cells, the authors are still not sure of the mechanism of action of CBD. They also did not think twice to explain the shortcomings of the research study. Dr. Blaskovich explained that considering that the results are in the initial stages, it is far prematurely for people to begin treating their CBD infections themselves.

The research study was also conducted in vitro (outside the human body), and there is a danger that the results of medical trials will not be the same. Numerous compounds have revealed anti-bacterial efficacy in petri dishes, however then failed at this crucial phase. It must also be pointed out that the two research studies were performed in cooperation with Botanix Pharmaceuticals Ltd, a pharmaceutical company concentrating on topical CBD products.

However, this research could be a crucial advance for CBD and the fight against antimicrobial resistance. CBD continues to have a good safety profile and is not considered poisonous even in big quantities. Thankfully, Dr. Blaskovich and his team strategy to continue their research.

Scroll to top